Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Find effective ways to build better saving habits that will enhance your financial situation. Start implementing these strategies for success.
17,928 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A major fund recently moved a sizable chunk of Osisko Development shares, prompting questions about what it means for...
When a senior executive at Maze Therapeutics sells a stake after positive trial data and solid quarterly results, inv...
Inflation stretches budgets and Social Security benefits, even with a potential bigger 2027 social security. This gui...
SpaceX's potential IPO has investors weighing a massive valuation against current profitability. This article breaks ...
As SpaceX captures headlines, a quieter but powerful growth wave is building in quantum computing. This guide highlig...
When a top executive sells stock, investors want to know if it signals trouble or simply personal planning. This arti...
A Phase 3 breakthrough unleashed a dramatic move in Cogent Biosciences. A large fund followed with a sizable stake, s...
Explore two powerful growth stories that fit the idea of brilliant growth stocks hold for the long term. NVIDIA leads...
A SpaceX IPO could reshape growth investing, creating upside for Rivian and other high-growth names. This guide break...
During 13F season, big investors reveal shifts in their portfolios. This piece explains the move, why Microsoft was f...
NVIDIA CEO Jensen Huang contends AI will drive a hiring surge, not a wave of job losses. The comments come as investo...